Literature DB >> 12061777

Acute and chronic treatment of ob/ob and db/db mice with AICAR decreases blood glucose concentrations.

Amy E Halseth1, Nancy J Ensor, Tommi A White, Stuart A Ross, Eric A Gulve.   

Abstract

The enzyme 5'AMP-activated protein kinase (AMPK) is activated by increases in intracellular AMP concentration through a complex interaction of phosphorylation and allosteric regulation. Actions of AMPK elucidated thus far suggest that AMPK may be a viable target for pharmacologic intervention in type II diabetes. Activation of AMPK is believed to mediate both the acute increase in skeletal muscle glucose uptake during exercise, as well as the adaptive responses to chronic exercise such as regulation of expression of components of the muscle glucose uptake system. In addition, AMPK is known to inhibit key enzymes involved in lipid and cholesterol synthesis, suggesting that activation of this kinase may also ameliorate dyslipidemia. To investigate the effects of AMPK activation in animal models of type II diabetes, db/db and ob/ob mice were administered 5-aminoimidazole-4-carboxamide 1-beta-ribofuranoside (AICAR) subcutaneously either acutely (single injection) or twice per day for 8 days (chronic treatment). Blood glucose was lowered transiently in both db/db and ob/ob mice by acute AICAR treatment, returning to basal levels approximately 3 h after AICAR administration. In response to chronic treatment, blood glucose (measured 18 h post-AICAR administration) was significantly decreased in both mouse models when compared to vehicle control groups, with morning blood glucose values on Day 8 being decreased approximately 30-35% in both mouse models. Chronic AICAR administration also resulted in an elevation of total Glut4 concentration in skeletal muscle from ob/ob mice, but not db/db mice. In contrast to the beneficial effects on glucose metabolism, AICAR treatment of db/db and ob/ob mice led to approximately a 2.5-3-fold increase in serum triglyceride levels compared to vehicle-treated controls. These data suggest that pharmacological activation of AMPK may enhance glucose uptake in individuals with type II diabetes, however, this benefit may be offset by the concomitant elevation in triglycerides. (c) 2002 Elsevier Science (USA).

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12061777     DOI: 10.1016/S0006-291X(02)00557-0

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  17 in total

Review 1.  Beyond AICA riboside: in search of new specific AMP-activated protein kinase activators.

Authors:  Bruno Guigas; Kei Sakamoto; Nellie Taleux; Sara M Reyna; Nicolas Musi; Benoit Viollet; Louis Hue
Journal:  IUBMB Life       Date:  2009-01       Impact factor: 3.885

Review 2.  Mitochondrial energetics in the kidney.

Authors:  Pallavi Bhargava; Rick G Schnellmann
Journal:  Nat Rev Nephrol       Date:  2017-08-14       Impact factor: 28.314

Review 3.  Small molecule adenosine 5'-monophosphate activated protein kinase (AMPK) modulators and human diseases.

Authors:  Sandeep Rana; Elizabeth C Blowers; Amarnath Natarajan
Journal:  J Med Chem       Date:  2014-08-28       Impact factor: 7.446

4.  Insulin signalling downstream of protein kinase B is potentiated by 5'AMP-activated protein kinase in rat hearts in vivo.

Authors:  S L Longnus; C Ségalen; J Giudicelli; M P Sajan; R V Farese; E Van Obberghen
Journal:  Diabetologia       Date:  2005-11-11       Impact factor: 10.122

5.  Suppression of 5'-nucleotidase enzymes promotes AMP-activated protein kinase (AMPK) phosphorylation and metabolism in human and mouse skeletal muscle.

Authors:  Sameer S Kulkarni; Håkan K R Karlsson; Ferenc Szekeres; Alexander V Chibalin; Anna Krook; Juleen R Zierath
Journal:  J Biol Chem       Date:  2011-08-26       Impact factor: 5.157

Review 6.  Stress signaling in the heart by AMP-activated protein kinase.

Authors:  Raymond Russell
Journal:  Curr Hypertens Rep       Date:  2006-12       Impact factor: 5.369

Review 7.  The AMPK signalling pathway coordinates cell growth, autophagy and metabolism.

Authors:  Maria M Mihaylova; Reuben J Shaw
Journal:  Nat Cell Biol       Date:  2011-09-02       Impact factor: 28.824

Review 8.  Past strategies and future directions for identifying AMP-activated protein kinase (AMPK) modulators.

Authors:  Sarah E Sinnett; Jay E Brenman
Journal:  Pharmacol Ther       Date:  2014-02-26       Impact factor: 12.310

9.  Novel protective mechanism of reducing renal cell damage in diabetes: Activation AMPK by AICAR increased NRF2/OGG1 proteins and reduced oxidative DNA damage.

Authors:  Samy L Habib; Anamika Yadav; Dawit Kidane; Robert H Weiss; Sitai Liang
Journal:  Cell Cycle       Date:  2016-09-09       Impact factor: 4.534

10.  Adenosine Monophosphate-Activated Protein Kinase (AMPK) as a New Target for Antidiabetic Drugs: A Review on Metabolic, Pharmacological and Chemical Considerations.

Authors:  Arie Gruzman; Gali Babai; Shlomo Sasson
Journal:  Rev Diabet Stud       Date:  2009-05-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.